Cite

HARVARD Citation

    Campillo-Gimenez, L. et al. (2015). Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. AIDS. p. . [Online]. 
  
Back to record